(doravirine + islatravir hydrate)

all catalysts(1)

News(3)

• Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
  Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
  biopharma_dive · 2mo ago
• Merck still sees ‘compelling’ outlook for Terns leukemia drug
  Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
  biopharma_dive · 3mo ago
• Merck adds to pharma’s AI push; Roche details MS drug results
  Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alli…
  biopharma_dive · 4mo ago